Liminatus Pharma, Inc.
LIMN
$1.28
-$0.03-2.29%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -- | -- | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 372,633.33% | -99.82% | |||
| Operating Income | -372,633.33% | 99.82% | |||
| Income Before Tax | 37,866.67% | 99.87% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 37,866.67% | 99.87% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 37,866.67% | 99.87% | |||
| EBIT | -372,633.33% | 99.82% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -- | 100.00% | |||
| Normalized Basic EPS | -- | 100.00% | |||
| EPS Diluted | -- | 100.00% | |||
| Normalized Diluted EPS | -- | 100.00% | |||
| Average Basic Shares Outstanding | -10.43% | -76.82% | |||
| Average Diluted Shares Outstanding | -10.43% | -76.82% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||